背景:唾液腺型癌症(SGTC)在组织学上是异质性的,并且可以影响唾液腺以外的器官。唾液腺外的一些肿瘤根据其独特的组织学特征被诊断出来。关于SGTC的跨器官综合研究是有限的。
方法:我们回顾性分析了唾液导管癌(SDC)患者的资料,腺样囊性癌(AdCC),粘液表皮样癌(MEC),上皮-肌上皮癌(EMC),腺泡细胞癌(AcCC),和多态性腺癌(PAC),他们在2009年至2019年期间访问了我们的机构。原发肿瘤部位分为四类;主要唾液腺,头/颈部(H/N),不包括(外)主要唾液腺(MSG)区域,支气管肺区域,和“其他人”。H/NexcMSG进一步分为三个子类别,鼻/鼻旁窦,口腔和咽/喉。
结果:我们确定了173例SGTC患者,有了SDC,AdCC,MEC,EMC,AcCC,PAC占20%,42%,27%,3%,8%,1%的病例,分别。最常见的主要部位是主要唾液腺(64%),其次是H/NexcMSG区域(27%),支气管肺区域,和“其他”,因此,非唾液腺起源占所有病例的9%。SDC患者,MEC,AcCC,或主要唾液腺和支气管肺区域的SGTC更频繁地通过手术治疗。MEC患者的总体生存时间明显优于SDC或EMC患者。
结论:这项跨器官研究强调了SGTC的临床意义,强调需要开发针对这种罕见疾病实体的新疗法。
BACKGROUND: Salivary gland-type cancers (SGTCs) are histologically heterogeneous and can affect organs other than the salivary glands. Some tumors outside the salivary glands are diagnosed on their unique histological characteristics. Comprehensive cross-organ studies on SGTCs are limited.
METHODS: We retrospectively analyzed the data of patients with salivary duct carcinoma (SDC), adenoid cystic carcinoma (AdCC), mucoepidermoid carcinoma (MEC), epithelial-myoepithelial carcinoma (EMC), acinic cell carcinoma (AcCC), and polymorphous adenocarcinoma (PAC) who visited our institution between 2009 and 2019. The primary tumor sites were classified into four categories; major salivary glands, head/neck (H/N) excluding (exc) major salivary glands (MSG) regions, broncho-pulmonary regions, and \"others\". H/N exc MSG was further divided into three subcategories, nasal/paranasal sinus, oral and pharynx/larynx.
RESULTS: We identified 173 patients with SGTCs, with SDC, AdCC, MEC, EMC, AcCC, and PAC accounting for 20%, 42%, 27%, 3%, 8%, and 1% of the cases, respectively. The most frequent primary site was the major salivary glands (64%), followed by H/N exc MSG regions (27%), broncho-pulmonary regions, and \"others\", thus non-salivary gland origins accounted for 9% of all cases. Patients with SDC, MEC, AcCC, or SGTC of the major salivary glands and broncho-pulmonary regions were more frequently treated by surgery. The overall survival time of the patients with MEC was significantly better than that of patients with SDC or EMC.
CONCLUSIONS: This cross-organ study highlights the clinical significance of SGTCs, underscoring the need for developing novel therapies for this rare disease entity.